Centanafadine

Centanafadine (INN; former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC₅₀ ratio of 1:6:14, respectively.^[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.^[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.^[7] As of 24 November 2025^[update], Otsuka's pipeline indicates it is in phase II and III clinical trials for a number of different applications to medical conditions.^{[8][9][10][11]}

Legal status

• US: Investigational New Drug

CAS Number

• 924012-43-1

PubChem CID

• 16095349

ChemSpider

• 17253639

Quick facts Legal status, Identifiers ...

Centanafadine

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
CAS Number	924012-43-1
PubChem CID	16095349
ChemSpider	17253639
UNII	D2A6T4UH9C
KEGG	D10697 Y
CompTox Dashboard (EPA)	DTXSID201045788
Chemical and physical data
Formula	C15H15N
Molar mass	209.292 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4
InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1 Key:HKHCSWPSUSWGLI-CABCVRRESA-N

Close